Drug intelligence / Profile preview

ART9

Development stage: Preclinical
Lead developer: Arnatar Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

ART9 is an antisense oligonucleotide (ASO) therapeutic candidate under development by Arnatar Therapeutics for the treatment of central nervous system (CNS) disorders. The drug is being developed using Arnatar's proprietary DARGER™ platform, which facilitates the design of RNA-based therapies. While the specific biological target and mechanism of action have not been publicly disclosed, ART9 is intended to modulate RNA expression to address neurological conditions. The program is currently in the discovery phase of development.

Beyond the preview

Go deeper on ART9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART9.

Explore the full profile